CRNX
Crinetics Pharmaceuticals, Inc.
Price Chart
Latest Quote
$35.87
+0.12 (+0.34%)
Current Price
| Previous Close | $35.75 |
| Open | $36.51 |
| Day High | $36.79 |
| Day Low | $35.05 |
| Volume | 1,492,319 |
Stock Information
| Shares Outstanding | 105.44M |
| Total Debt | $47.85M |
| Cash Equivalents | $1.29B |
| Revenue | $18.07M |
| Net Income | $-496.39M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.78B |
| EPS (TTM) | $-5.14 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.54B |
| Sales | $18.07M |
| Income | $-496.39M |
| Book/sh | $12.16 |
| Cash/sh | $12.25 |
| Employees | 594 |
Financial Ratios
| Quick Ratio | 18.25 |
| Current Ratio | 18.60 |
| Debt/Eq | 3.74 |
Returns & Margins
| ROA | -24.69% |
| ROE | -39.17% |
| Operating Margin | -1307.79% |
Ownership
| Insider Ownership | 1.59% |
| Institutional Ownership | 120.17% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.52 |
| P/S | 209.32 |
| P/B | 2.95 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $83.14 |
Technical Indicators
| SMA20 | $34.96 |
| SMA50 | $37.23 |
| SMA200 | $41.74 |
| RSI | 51.26 |
| ATR | 1.6409 |
| Shares Float | 95.58M |
| Short Float | 14.04% |
| Short Ratio | 9.38 |
| Volatility | 0.24 |
| Rel Volume | 1.99 |
Performance History
| Week | +6.98% |
| Month | +2.66% |
| Quarter | +0.14% |
| 6 Months | -26.21% |
| YTD | -23.24% |
| Year | +16.27% |
| 3 Years | +66.22% |
| 5 Years | +111.25% |
| 10 Years | +46.35% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $35.87 | 2,013,900 |
| 2026-06-17 | $35.75 | 743,600 |
| 2026-06-16 | $35.00 | 694,900 |
| 2026-06-15 | $35.12 | 931,200 |
| 2026-06-12 | $34.47 | 1,039,500 |
| 2026-06-11 | $33.53 | 1,776,600 |
| 2026-06-10 | $34.32 | 625,300 |
| 2026-06-09 | $34.97 | 884,500 |
| 2026-06-08 | $33.48 | 993,800 |
| 2026-06-05 | $32.92 | 863,200 |
| 2026-06-04 | $34.63 | 1,090,500 |
| 2026-06-03 | $33.09 | 858,000 |
| 2026-06-02 | $32.61 | 978,100 |
| 2026-06-01 | $34.52 | 799,100 |
| 2026-05-29 | $35.55 | 1,931,200 |
| 2026-05-28 | $36.01 | 993,400 |
| 2026-05-27 | $36.79 | 861,600 |
| 2026-05-26 | $36.78 | 716,500 |
| 2026-05-22 | $36.80 | 702,400 |
| 2026-05-21 | $37.09 | 740,800 |
| 2026-05-20 | $36.27 | 666,300 |
| 2026-05-19 | $34.94 | 932,200 |
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
đ° Latest News
Leerink Upholds Outperform Rating for Crinetics Pharmaceuticals (CRNX)
Insider Monkey âĸ 2026-06-17T15:55:33Z
Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
Insider Monkey âĸ 2026-06-11T10:20:27Z
A Look At Crinetics Pharmaceuticals (CRNX) Valuation As New Endocrine Data Heads To ENDO 2026
Simply Wall St. âĸ 2026-06-04T13:12:06Z
What Do Analysts Say About Crinetics Pharmaceuticals (CRNX)?
Insider Monkey âĸ 2026-05-29T10:31:08Z
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?
Motley Fool âĸ 2026-05-18T18:10:27Z
Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%
Simply Wall St. âĸ 2026-05-13T12:11:59Z
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Simply Wall St. âĸ 2026-05-11T14:18:09Z
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Momentum
Simply Wall St. âĸ 2026-05-09T19:09:42Z
Crinetics (CRNX) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-08T14:37:57Z
Crinetics Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-08T12:30:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,076,000 | $0 | $0 | - |
| Cost Of Revenue | $1,076,000 | $0 | $0 | - |
| Total Revenue | $7,696,000 | $1,039,000 | $4,013,000 | $4,737,000 |
| Operating Revenue | $7,696,000 | $1,039,000 | $4,013,000 | $4,737,000 |
| Expenses | ||||
| Total Expenses | $524,465,000 | $339,893,000 | $226,621,000 | $172,619,000 |
| Other Income Expense | $-357,000 | $-989,000 | $-5,357,000 | $-353,000 |
| Other Non Operating Income Expenses | $-357,000 | $-519,000 | $-159,000 | $57,000 |
| Net Non Operating Interest Income Expense | $51,989,000 | $41,435,000 | $13,436,000 | $4,317,000 |
| Operating Expense | $523,389,000 | $339,893,000 | $226,621,000 | $172,619,000 |
| General And Administrative Expense | $191,331,000 | $99,737,000 | $58,094,000 | $42,394,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-465,317,000 | $-298,408,000 | $-214,529,000 | $-163,918,000 |
| Net Interest Income | $51,989,000 | $41,435,000 | $13,436,000 | $4,317,000 |
| Interest Income | $51,989,000 | $41,435,000 | $13,436,000 | $4,317,000 |
| Normalized Income | $-465,317,000 | $-298,408,000 | $-214,529,000 | $-164,518,000 |
| Net Income From Continuing And Discontinued Operation | $-465,317,000 | $-298,408,000 | $-214,529,000 | $-163,918,000 |
| Total Operating Income As Reported | $-516,769,000 | $-338,854,000 | $-222,608,000 | $-167,882,000 |
| Net Income Common Stockholders | $-465,317,000 | $-298,408,000 | $-214,529,000 | $-163,918,000 |
| Net Income | $-465,317,000 | $-298,408,000 | $-214,529,000 | $-163,918,000 |
| Net Income Including Noncontrolling Interests | $-465,317,000 | $-298,408,000 | $-214,529,000 | $-163,918,000 |
| Net Income Continuous Operations | $-465,317,000 | $-298,408,000 | $-214,529,000 | $-163,918,000 |
| Pretax Income | $-465,137,000 | $-298,408,000 | $-214,529,000 | $-163,918,000 |
| Earnings From Equity Interest | $0 | $-470,000 | $-5,198,000 | $-1,010,000 |
| Interest Income Non Operating | $51,989,000 | $41,435,000 | $13,436,000 | $4,317,000 |
| Operating Income | $-516,769,000 | $-338,854,000 | $-222,608,000 | $-167,882,000 |
| Gross Profit | $6,620,000 | $1,039,000 | $4,013,000 | - |
| Per Share | ||||
| Diluted EPS | $-4.95 | $-3.69 | $-3.69 | $-3.15 |
| Basic EPS | $-4.95 | $-3.69 | $-3.69 | $-3.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-512,879,000 | $-336,069,000 | $-221,510,000 | $-167,499,000 |
| Reconciled Depreciation | $3,890,000 | $2,785,000 | $1,098,000 | $983,000 |
| EBITDA (Bullshit earnings) | $-512,879,000 | $-336,069,000 | $-221,510,000 | $-166,899,000 |
| EBIT | $-516,769,000 | $-338,854,000 | $-222,608,000 | $-167,882,000 |
| Diluted Average Shares | $94,057,000 | $80,783,000 | $58,071,000 | $51,982,000 |
| Basic Average Shares | $94,057,000 | $80,783,000 | $58,071,000 | $51,982,000 |
| Diluted NI Availto Com Stockholders | $-465,317,000 | $-298,408,000 | $-214,529,000 | $-163,918,000 |
| Tax Provision | $180,000 | $0 | $0 | - |
| Research And Development | $332,058,000 | $240,156,000 | $168,527,000 | $130,225,000 |
| Selling General And Administration | $191,331,000 | $99,737,000 | $58,094,000 | $42,394,000 |
| Other Gand A | $191,331,000 | $99,737,000 | $58,094,000 | $42,394,000 |
| Total Unusual Items | - | - | - | $600,000 |
| Total Unusual Items Excluding Goodwill | - | - | - | $600,000 |
| Gain On Sale Of Security | - | - | - | $600,000 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $992,083,000 | $1,324,805,000 | $539,106,000 | $316,328,000 |
| Total Assets | $1,126,257,000 | $1,434,592,000 | $635,353,000 | $352,176,000 |
| Total Non Current Assets | $77,915,000 | $59,204,000 | $61,200,000 | $6,992,000 |
| Other Non Current Assets | $23,127,000 | $3,629,000 | $3,300,000 | $1,338,000 |
| Current Assets | $1,048,342,000 | $1,375,388,000 | $574,153,000 | $345,184,000 |
| Other Current Assets | $17,839,000 | $20,819,000 | $448,000 | $1,930,000 |
| Restricted Cash | $0 | $500,000 | $0 | - |
| Inventory | $2,022,000 | $0 | - | - |
| Receivables | $592,000 | $0 | $9,351,000 | $3,030,000 |
| Accounts Receivable | $592,000 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $1,027,889,000 | $1,354,069,000 | $558,555,000 | $334,425,000 |
| Cash And Cash Equivalents | $101,536,000 | $264,545,000 | $54,897,000 | $32,672,000 |
| Prepaid Assets | - | $11,142,000 | $5,799,000 | $5,799,000 |
| Other Receivables | - | $86,000 | $5,463,000 | $605,000 |
| Taxes Receivable | - | $74,000 | $747,000 | $937,000 |
| Accrued Interest Receivable | - | $8,310,000 | $3,051,000 | $1,353,000 |
| Financial Assets | - | - | $0 | $668,000 |
| Debt | ||||
| Total Debt | $48,541,000 | $51,722,000 | $51,728,000 | $3,075,000 |
| Long Term Debt And Capital Lease Obligation | $42,052,000 | $44,570,000 | $47,555,000 | $2,024,000 |
| Current Debt And Capital Lease Obligation | $6,489,000 | $7,152,000 | $4,173,000 | $1,051,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $134,174,000 | $109,787,000 | $96,247,000 | $35,848,000 |
| Total Non Current Liabilities Net Minority Interest | $49,102,000 | $50,103,000 | $52,305,000 | $8,125,000 |
| Other Non Current Liabilities | $3,240,000 | $829,000 | - | - |
| Non Current Deferred Liabilities | $3,810,000 | $4,704,000 | $4,750,000 | $6,101,000 |
| Current Liabilities | $85,072,000 | $59,684,000 | $43,942,000 | $27,723,000 |
| Current Deferred Liabilities | $1,235,000 | $2,176,000 | $2,056,000 | $2,240,000 |
| Payables And Accrued Expenses | $41,770,000 | $21,469,000 | $23,196,000 | $15,351,000 |
| Payables | $22,611,000 | $5,853,000 | $6,548,000 | $6,883,000 |
| Accounts Payable | $22,611,000 | $5,853,000 | $6,548,000 | $6,883,000 |
| Other Current Liabilities | - | - | - | $1,051,000 |
| Equity | ||||
| Common Stock Equity | $992,083,000 | $1,324,805,000 | $539,106,000 | $316,328,000 |
| Total Equity Gross Minority Interest | $992,083,000 | $1,324,805,000 | $539,106,000 | $316,328,000 |
| Stockholders Equity | $992,083,000 | $1,324,805,000 | $539,106,000 | $316,328,000 |
| Other Equity Interest | $-112,000 | - | - | - |
| Gains Losses Not Affecting Retained Earnings | $1,865,000 | $963,000 | $977,000 | $-3,931,000 |
| Other Equity Adjustments | $1,865,000 | $963,000 | $977,000 | $-3,931,000 |
| Retained Earnings | $-1,417,427,000 | $-952,110,000 | $-653,702,000 | $-439,173,000 |
| Long Term Equity Investment | - | $0 | $470,000 | $0 |
| Other | ||||
| Ordinary Shares Number | $95,575,000 | $92,926,000 | $68,175,000 | $53,877,000 |
| Share Issued | $95,575,000 | $92,926,000 | $68,175,000 | $53,877,000 |
| Tangible Book Value | $992,083,000 | $1,324,805,000 | $539,106,000 | $316,328,000 |
| Invested Capital | $992,083,000 | $1,324,805,000 | $539,106,000 | $316,328,000 |
| Working Capital | $963,270,000 | $1,315,704,000 | $530,211,000 | $317,461,000 |
| Capital Lease Obligations | $48,541,000 | $51,722,000 | $51,728,000 | $3,075,000 |
| Total Capitalization | $992,083,000 | $1,324,805,000 | $539,106,000 | $316,328,000 |
| Capital Stock | $2,407,757,000 | $2,275,952,000 | $1,191,831,000 | $759,432,000 |
| Common Stock | $2,407,757,000 | $2,275,952,000 | $1,191,831,000 | $759,432,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $3,810,000 | $4,704,000 | $4,750,000 | $6,101,000 |
| Long Term Capital Lease Obligation | $42,052,000 | $44,570,000 | $47,555,000 | $2,024,000 |
| Current Deferred Revenue | $1,235,000 | $2,176,000 | $2,056,000 | $2,240,000 |
| Current Capital Lease Obligation | $6,489,000 | $7,152,000 | $4,173,000 | $1,051,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $35,578,000 | $28,887,000 | $14,517,000 | $9,081,000 |
| Current Accrued Expenses | $19,159,000 | $15,616,000 | $16,648,000 | $8,468,000 |
| Net PPE | $54,788,000 | $55,575,000 | $57,430,000 | $4,986,000 |
| Accumulated Depreciation | $-7,952,000 | $-7,732,000 | $-5,068,000 | $-4,084,000 |
| Gross PPE | $62,740,000 | $63,307,000 | $62,498,000 | $9,070,000 |
| Leases | $10,003,000 | $11,900,000 | $9,837,000 | $3,516,000 |
| Other Properties | $50,452,000 | $49,200,000 | $50,802,000 | $4,654,000 |
| Machinery Furniture Equipment | $2,285,000 | $2,207,000 | $1,859,000 | $900,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $926,353,000 | $1,089,524,000 | $503,658,000 | $301,753,000 |
| Investments And Advances | - | $0 | $470,000 | $0 |
| Investmentsin Subsidiariesat Cost | - | $0 | $470,000 | $0 |
| Duefrom Related Parties Current | - | $0 | $90,000 | $135,000 |
| Restricted Common Stock | - | - | - | - |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-383,684,000 | $-234,038,000 | $-173,286,000 | $-116,861,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-377,922,000 | $-230,194,000 | $-168,598,000 | $-115,205,000 |
| Cash Flow From Continuing Operating Activities | $-377,922,000 | $-230,194,000 | $-168,598,000 | $-115,205,000 |
| Operating Gains Losses | $50,000 | $521,000 | $5,204,000 | $410,000 |
| Investing Activities | ||||
| Capital Expenditure | $-5,762,000 | $-3,844,000 | $-4,688,000 | $-1,656,000 |
| Investing Cash Flow | $173,908,000 | $-574,817,000 | $-200,413,000 | $-173,980,000 |
| Cash Flow From Continuing Investing Activities | $173,908,000 | $-574,817,000 | $-200,413,000 | $-173,980,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-14,982,000 | $-541,000 | - |
| Issuance Of Capital Stock | $0 | $985,030,000 | $369,560,000 | $117,242,000 |
| Financing Cash Flow | $40,611,000 | $1,014,659,000 | $391,235,000 | $121,963,000 |
| Cash Flow From Continuing Financing Activities | $40,611,000 | $1,014,659,000 | $391,235,000 | $121,963,000 |
| Net Common Stock Issuance | $0 | $970,048,000 | $369,019,000 | $117,242,000 |
| Common Stock Issuance | $0 | $985,030,000 | $369,560,000 | $117,242,000 |
| Other | ||||
| End Cash Position | $102,336,000 | $265,845,000 | $56,197,000 | $33,973,000 |
| Beginning Cash Position | $265,845,000 | $56,197,000 | $33,973,000 | $201,195,000 |
| Effect Of Exchange Rate Changes | $-106,000 | $0 | $0 | - |
| Changes In Cash | $-163,403,000 | $209,648,000 | $22,224,000 | $-167,222,000 |
| Proceeds From Stock Option Exercised | $40,611,000 | $44,611,000 | $22,216,000 | $4,721,000 |
| Common Stock Payments | $0 | $-14,982,000 | $-541,000 | - |
| Net Investment Purchase And Sale | $179,670,000 | $-570,973,000 | $-195,725,000 | $-172,324,000 |
| Sale Of Investment | $1,184,097,000 | $575,799,000 | $337,132,000 | $157,493,000 |
| Purchase Of Investment | $-1,004,427,000 | $-1,146,772,000 | $-532,857,000 | $-329,817,000 |
| Net PPE Purchase And Sale | $-5,762,000 | $-3,844,000 | $-4,688,000 | $-1,656,000 |
| Purchase Of PPE | $-5,762,000 | $-3,844,000 | $-4,688,000 | $-1,656,000 |
| Change In Working Capital | $4,842,000 | $7,411,000 | $5,753,000 | $18,612,000 |
| Change In Other Working Capital | $-1,835,000 | $74,000 | $-1,535,000 | $8,341,000 |
| Change In Other Current Liabilities | $-3,181,000 | $-6,000 | $-546,000 | $-938,000 |
| Change In Payables And Accrued Expense | $28,983,000 | $13,317,000 | $12,357,000 | - |
| Change In Prepaid Assets | $-16,511,000 | $-5,974,000 | $-4,523,000 | $215,000 |
| Change In Inventory | $-2,022,000 | $0 | $0 | - |
| Change In Receivables | $-592,000 | $0 | $0 | $10,994,000 |
| Changes In Account Receivables | $-592,000 | $0 | $0 | $10,994,000 |
| Other Non Cash Items | $3,014,000 | $3,042,000 | $-790,000 | $406,000 |
| Stock Based Compensation | $91,024,000 | $69,386,000 | $40,937,000 | $28,268,000 |
| Amortization Of Securities | $-15,425,000 | $-14,931,000 | $-6,271,000 | $34,000 |
| Depreciation Amortization Depletion | $3,890,000 | $2,785,000 | $1,098,000 | $983,000 |
| Depreciation And Amortization | $3,890,000 | $2,785,000 | $1,098,000 | $983,000 |
| Earnings Losses From Equity Investments | $0 | $470,000 | $5,198,000 | $1,010,000 |
| Gain Loss On Sale Of PPE | $50,000 | $51,000 | $6,000 | $0 |
| Net Income From Continuing Operations | $-465,317,000 | $-298,408,000 | $-214,529,000 | $-163,918,000 |
| Gain Loss On Investment Securities | - | - | - | $-600,000 |
| Change In Payable | - | - | - | - |
| Change In Account Payable | - | - | - | - |
Fetched: 2026-06-16